 |
|
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
Intest Res. 2017;15(4):487-494. Published online 2017 Oct 23 DOI: https://doi.org/10.5217/ir.2017.15.4.487
|
|
Citations to this article as recorded by
 Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
Advances in Digestive Medicine.2023; 10(1): 28. CrossRef Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study
Nai‐Yu Chen, Chiao‐Hsiung Chuang, Yu‐Ching Chang, Yea‐Huei Kao Yang, Peng‐Hsu Chen, Ching‐Lan Cheng
Clinical Pharmacology & Therapeutics.2023; 114(4): 914. CrossRef Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C
Clinical Gastroenterology and Hepatology.2022; 20(8): 1671. CrossRef Adalimumab Efficacy for Management of Inflammatory Bowel Disease in Southwest Region of Iran
Pezhman Alavinejad, Sana Delavari, Abazar Parsi, Ali Akbar Shayesteh
Modern Care Journal.2022;[Epub] CrossRef Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
Intestinal Research.2019; 17(1): 54. CrossRef Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
Caifang Gao, Lijuan Liu, Yangyang Zhou, Zhaoxiang Bian, Shengpeng Wang, Yitao Wang
Chinese Medicine.2019;[Epub] CrossRef Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
|